Author:
Enkelmann Julia, ,Gassowski Martyna,Nielsen Stine,Wenz Benjamin,Roß Stefan,Marcus Ulrich,Bremer Viviane,Zimmermann Ruth
Abstract
Abstract
Background
In Germany, risk of hepatitis C virus (HCV) infection is highest among people who inject drugs (PWID). New injectors (NI) are particularly vulnerable for HCV-acquisition, but little is known about health seeking behaviour and opportunities for intervention in this group. We describe characteristics, HCV prevalence, estimated HCV incidence and awareness of HCV-status among NIs and missed opportunities for hepatitis C testing.
Methods
People who had injected drugs in the last 12 months were recruited into a cross-sectional serobehavioural study using respondent-driven sampling in 8 German cities, 2011–2014. Data on sociodemographic characteristics, previous HCV testing and access to care were collected through questionnaire-based interviews. Capillary blood was tested for HCV. People injecting drugs < 5 years were considered NI.
Results
Of 2059 participants with available information on duration of injection drug use, 232 (11% were NI. Estimated HCV incidence among NI was 19.6 infections/100 person years at risk (95% CI 16–24). Thirty-six percent of NI were HCV-positive (thereof 76% with detectable RNA) and 41% of those HCV-positive were unaware of their HCV-status. Overall, 27% of NI reported never having been HCV-tested. Of NI with available information, more than 80% had attended low-threshold drug services in the last 30 days, 24% were released from prison in the last 12 months and medical care was most commonly accessed in hospitals, opioid substitution therapy (OST)-practices, practices without OST and prison hospitals.
Conclusion
We found high HCV-positivity and low HCV-status awareness among NI, often with missed opportunities for HCV-testing. To increase early diagnosis and facilitate treatment, HCV-testing should be offered in all facilities, where NI can be reached, especially low-threshold drug services and addiction therapy, but also prisons, hospitals and practices without OST.
Funder
German Federal Ministry of Health
Robert Koch Institute
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Medicine (miscellaneous)
Reference37 articles.
1. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC_SA 3.0 IGO.
2. German Federal Ministry of Health and Federal Ministry for Economic Cooperation and Development. Integrated strategy for HIV, hepatitis B and C and other sexually transmitted infections. Available from https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Praevention/Broschueren/Strategy_HIV_HEP_STI.pdf, Accessed 09 10 2019. 2016.
3. Webster D, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;2015(385):1124–35.
4. Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, et al. Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5–6):707–15.
5. Zimmermann R, Meurs L, Schmidt D, Kollan C, Dudareva S, Bremer V. Zur Situation bei wichtigen Infektionskarankheiten in Deutschland. Hepatitis C im Jahr 2017. Epid Bull 2018;29:271–281. doi 1017886/EpiBull-2018-035. 2018.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献